미국의 중재적 종양학 시장 규모, 점유율, 동향 분석 보고서 : 수기별, 시술별, 용도별, 최종 용도별, 부문 예측(2025-2030년)

U.S. Interventional Oncology Market Trends:

The U.S. interventional oncology market size was estimated at USD 998.4 million in 2024 and is projected to grow at a CAGR of 8.17% from 2025 to 2030. The market is growing due to increasing cancer prevalence, rising technological advancements in minimally invasive procedures, increasing investments in the field of interventional oncology, and the growing geriatric population in the country.

The rising prevalence of cancer in the U.S. is a major factor driving the market growth. According to the American Cancer Society, around. 2,041,910 new cancers are estimated to occur in the U.S. in 2025, while cancer is expected to cause 618,120 mortalities in the same year. As traditional treatments such as chemotherapy and radiation therapy often have significant side effects, minimally invasive alternatives such as radiofrequency ablation and microwave ablation are gaining popularity. These procedures offer localized tumor destruction with minimal damage to surrounding tissues, improving patient outcomes and driving demand for interventional oncology solutions.

Continuous technological advancements in interventional oncology are enhancing the effectiveness and adoption of these procedures. Companies operating in the market are focusing on innovation to introduce advanced products in the market, thereby improving patient outcomes. For instance, in September 2023, Profound Medical obtained 510(k) clearance from the U.S. FDA for its TULSA-PRO Thermal Boost module, which allows surgeons to temporarily elevate ablation temperatures in specific areas of the prostate. The Thermal Boost feature has led to improved treatment results in 88% of prostate cancer cases, thereby enhancing both efficacy and workflow efficiency. Such advancements improve clinical outcomes and increase the appeal of interventional oncology among healthcare providers.

The growing investment in interventional oncology from both public and private sectors is accelerating market expansion in the U.S. Government initiatives, research funding, and venture capital investments are supporting the development of innovative treatment modalities to improve precision oncology, ensuring that interventional techniques are integrated into mainstream cancer care. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping for precision-guided interventions for HCC.

U.S. Interventional Oncology Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. interventional oncology market report based on techniques, procedures, application, end use:

• Technique Outlook (Revenue, USD Million, 2018 - 2030)
• Ablation Therapies
  • Radiofrequency Ablation (RFA)
  • Microwave Ablation (MWA)
  • Cryoablation
  • Laser Ablation
  • Irreversible Electroporation (IRE)
• Embolization Therapies
  • Transarterial Chemoembolization (TACE)
  • Transarterial Radioembolization (TARE)
• Biopsy Techniques
  • Core Needle Biopsy
  • Fine Needle Aspiration (FNA)
• Targeted Therapy Delivery Systems
  • Drug-Eluting Beads
  • Radioembolization
  • Drug-Eluting Stents
  • Injectable Hydrogels and Nanoparticles
  • Other Targeted Therapy Systems
• Image-Guided Procedures
  • Ultrasound Guidance
  • CT Scan Guidance
  • MRI Guidance
  • Fluoroscopy Guidance
• Procedure Outlook (Revenue, USD Million, 2018 - 2030)
• Tumor Ablation
• Tumor Biopsy
• Vascular Interventions
• Palliative Care
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Specialty Clinics
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Technique Segment
  • 1.2.2. Procedure Segment
  • 1.2.3. Application Segment
  • 1.2.4. End-use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. U.S. Interventional Oncology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Increasing technological advancements in minimally invasive procedures
    • 3.2.1.3. Growing geriatric population
    • 3.2.1.4. Increasing investments in the field of interventional oncology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with interventional oncology
    • 3.2.2.2. Requirement of highly skilled professionals
• 3.3. Interventional Oncology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Interventional Oncology Market: Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Interventional Oncology Market Technique Movement Analysis
• 4.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
• 4.4. Ablation Therapies
  • 4.4.1. Ablation Therapies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Radiofrequency Ablation (RFA)
    • 4.4.2.1. Radiofrequency Ablation (RFA) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Microwave Ablation (MWA)
    • 4.4.3.1. Microwave Ablation (MWA) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Cryoablation
    • 4.4.4.1. Cryoablation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Laser Ablation
    • 4.4.5.1. Laser Ablation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Irreversible Electroporation (IRE)
    • 4.4.6.1. Irreversible Electroporation (IRE) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Embolization Therapies
  • 4.5.1. Embolization Therapies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.2. Transarterial Chemoembolization (TACE)
    • 4.5.2.1. Transarterial Chemoembolzation (TACE) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.3. Transarterial Radioembolization (TARE)
    • 4.5.3.1. Transarterial Radioembolization (TARE) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Biopsy Techniques
  • 4.6.1. Biopsy Techniques market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6.2. Core Needle Biopsy
    • 4.6.2.1. Core Needle Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6.3. Fine Needle Aspiration (FNA)
    • 4.6.3.1. Fine Needle Aspiration (FNA) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Targeted Therapy Delivery Systems
  • 4.7.1. Drug Delivery Systems market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.2. Drug-Eluting Beads
    • 4.7.2.1. Drug-Eluting Beads market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.3. Radioembolization
    • 4.7.3.1. Radioembolization market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.4. Drug-Eluting Stents
    • 4.7.4.1. Drug-Eluting Stents market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.5. Injectable Hydrogels and Nanoparticles
    • 4.7.5.1. Injectable Hydrogels and Nanoparticles market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.6. Other Targeted Therapy Systems
    • 4.7.6.1. Other Targeted Therapy Systems market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.8. Image-Guided Procedures
  • 4.8.1. Image-Guided Procedures market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8.2. Ultrasound Guidance
    • 4.8.2.1. Ultrasound Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8.3. CT Scan Guidance
    • 4.8.3.1. CT Scan Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8.4. MRI Guidance
    • 4.8.4.1. MRI Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8.5. Fluoroscopy Guidance
    • 4.8.5.1. Fluoroscopy Guidance market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Interventional Oncology Market: Procedures Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Interventional Oncology Market Procedures Movement Analysis
• 5.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Procedures, 2018 to 2030 (USD Million)
• 5.4. Tumor Ablation
  • 5.4.1. Tumor Ablation market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Tumor Biopsy
  • 5.5.1. Tumor Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Vascular Interventions
  • 5.6.1. Vascular Interventions market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Palliative Care
  • 5.7.1. Palliative Care market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Interventional Oncology Materials Market: Applications Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Interventional Oncology Market Applications Movement Analysis
• 6.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Applications, 2018 to 2030 (USD Million)
• 6.4. Liver Cancer
  • 6.4.1. Liver Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Lung Cancer
  • 6.5.1. Lung Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Kidney Cancer
  • 6.6.1. Kidney Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Prostate Cancer
  • 6.7.1. Prostate Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Breast Cancer
  • 6.8.1. Breast Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Other Cancer
  • 6.9.1. Other Cancer market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. U.S. Interventional Oncology Market: End-use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Interventional Oncology Market End Use Movement Analysis
• 7.3. U.S. Interventional Oncology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Specialty Clinics
  • 7.5.1. Specialty Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Medtronic
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Boston Scientific Corporation
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Johnson & Johnson (Ethicon)
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Cook Medical
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. AngioDynamics Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Stryker
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Terumo Corporation
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Siemens Healthineers (Varian)
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Teleflex Incorporated
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Profound Medical
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives